IL ‐ 17A Promotes NETs Formation via the PKCζ – ERK – ROS – PAD4 Pathway in a Mouse Model of Ischemic Stroke
CNS Neuroscience & Therapeutics · 2026
DOI: 10.1002/cns.70825 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Chang Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Interleukin-17, Ischemic Stroke, Protein-Arginine Deiminase Type 4, Extracellular Traps. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Tsinghua Changgung Hospital Fund, The Beijing High-Level Innovation and Entrepreneurship Talent Support Program young backbone talent projects.
Themen: Schlaganfall
Abstract (Originalsprache)
Aims
Interleukin‐17A (IL‐17A) aggravates poststroke neurological damage and enhances neutrophil extracellular traps (NETs) formation, yet the underlying mechanism remains unclear. This study aimed to elucidate how IL‐17A regulates NETs generation after ischemic stroke.
Methods
Using a mouse middle cerebral artery occlusion (MCAO) model, we administered the Peptidylarginine deiminase 4 (PAD4) inhibitor GSK484 or an IL‐17A‐neutralizing antibody (IL‐17mAb). Infarct volume and neurological function were assessed, and protein expression of PAD4, myeloperoxidase (MPO), citrullinated histones H3 (CitH3), protein kinase Cζ (PKCζ), and phosphorylated extracellular signal‐regulated kinase (p‐ERK) was evaluated. IL‐17A − / − mice and primary neutrophils were used to further validate the signaling pathway.
Results
Inhibiting PAD4 with GSK484 can significantly reduce infarct size, improve neurological outcomes, and decrease PAD4, MPO, and CitH3 protein levels. Subsequently, we found that IL‐17mAb treatment can reduce the expression of PAD4, MPO, and CitH3 in the peri‐infarct area, as well as the expression of PKC‐ζ and p‐ERK. Similarly, the expression of PAD4 and CitH3 decreased in the peri‐infarct area of IL‐17A − / − MCAO mice. Finally, we verified IL‐17A induced PAD4 upregulation via the PKCζ–ERK–ROS axis in vitro.
Conclusion
IL‐17A promotes NETs formation by upregulating PAD4 through the PKCζ–ERK–ROS pathway, exacerbating ischemic brain injury. Targeting this axis may offer a novel therapeutic strategy for stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
ORCID-Profile: Wei Su, Qingqing Dai
Förderung
- National Natural Science Foundation of China
- Beijing Tsinghua Changgung Hospital Fund
- The Beijing High-Level Innovation and Entrepreneurship Talent Support Program young backbone talent projects
Zitieren
APA
Liu, C., Chen, Q., Chen, W., Han, X., Qiao, X., Guo, J., Su, W., & Dai, Q. (2026). IL ‐ 17A Promotes NETs Formation via the PKCζ – ERK – ROS – PAD4 Pathway in a Mouse Model of Ischemic Stroke. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70825
Vancouver
Liu C, Chen Q, Chen W, Han X, Qiao X, Guo J, et al. IL ‐ 17A Promotes NETs Formation via the PKCζ – ERK – ROS – PAD4 Pathway in a Mouse Model of Ischemic Stroke. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70825
BibTeX
@article{Liu2026,
author = {Liu, Chang and Chen, Qi and Chen, Weijia and Han, Xinyue and Qiao, Xiaowen and Guo, Jun and Su, Wei and Dai, Qingqing},
title = {IL ‐ 17A Promotes NETs Formation via the PKCζ – ERK – ROS – PAD4 Pathway in a Mouse Model of Ischemic Stroke},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
doi = {10.1002/cns.70825}
}
EUVIMED